Europe Iodinated Contrast Media in Interventional X-Ray Market By Route of Administration (Intravenous, Oral, Rectal, Others), Indication (Cardiology, Neurology, General Surgery, Oncology, Urology), Agent Type (Non-Ionic, Ionic), End User (Hospital, Specialty Clinics, Diagnostic Centers, Ambulatory Surgical Centers, Research & Academic Institutes), By Country (Germany, Italy, France, U.K., Spain, Russia, Netherlands, Switzerland, Belgium, Turkey, and Rest of Europe), Market Trends and Forecast to 2027
Market Analysis and Insights: Europe Iodinated contrast media in interventional X-ray Market
Iodinated contrast media in interventional X-ray market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses that the market is growing with a CAGR of 4.9% in the forecast period of 2020 to 2027 and expected to reach USD 886.27 million by 2027 from USD 610.51 million in 2019. Increase in the research and developmental activities of contrast agents and high use of interventional X-ray in various diagnosis applications are the major factors for the market growth.
Iodinated contrast media in interventional X-ray are increasing with increasing demand for diagnosis of chronic diseases. Increasing prevalence of cardiac diseases and growing preference for interventional X-rays technique healthcare over the globe have increased the adoption of diagnostic centers globally. The need for diagnostic imaging has increased resulting to the contribution to the medical costs and also by providing exposure to the ionizing radiation. Moreover, rising incidence of chronic diseases, increasing prevalence of cardiac diseases and rising diagnostic centers across the region led to the growth of iodinated contrast media in interventional X-ray market. The need for diagnostic imaging has increased resulting to the contribution to the medical costs and also by providing exposure to the ionizing radiation.
This iodinated contrast media in interventional X-ray market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Europe Iodinated Contrast Media in Interventional X-Ray Market Scope and Market Size
Iodinated contrast media in interventional X-ray market is segmented on the basis of route of administration, indication, agent type and end user. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
Based on route of administration, iodinated contrast media in interventional X-ray market is segmented into oral, intravenous, rectal, others. Intravenous segment is dominating the market because it’s most preferred route of administration among interventional radiologist due to their characteristics.
Based on agent type, iodinated contrast media in interventional X-ray market is segmented into ionic and non-ionic. Non-ionic segment is dominating the market as these iodinated contrast agents are mainly used in cardio-interventional diagnostics procedure for enhancing the perfusion in tissues and the blood.
Based on indication, iodinated contrast media in interventional X-ray market is segmented into cardiology, oncology, urology, general surgery and neurology. Cardiology segment is dominating the market due to high use of iodinated contrast media in chronic disease such as cardiovascular disease and other heart disease which requires continuous monitoring through X-rays for treatment.
Based on end user, the market is segmented into hospital, specialty clinics, diagnostic centers, ambulatory surgical centres, research & academic institutes. Hospital segment is dominating the market throughout the forecast period as hospital facilities are first line of treatment place for interventional radiology diagnostic procedure.
Iodinated Contrast Media in Interventional X-Ray Market Country Level Analysis
Europe market is analysed and market size information is provided by country by route of administration, agent type, indication, and end user as referenced above.
The countries covered in the iodinated contrast media in interventional X-ray market report are Germany, Italy, France, U.K., Spain, Russia, Netherlands, Switzerland, Belgium, Turkey, and Rest of Europe in Europe.
Europe iodinated contrast media in interventional X-ray market is growing due to awareness about interventional diagnosis and treatment of the chronic disease is expected to grow at the significant growth rate in the forecast period of 2020 to 2027. Europe iodinated contrast media in interventional X-ray market is growing due to government initiatives to increase the awareness about cancer and cardiac diagnosis, innovative contrast agent products being launched by several companies is expected to grow at the significant growth rate in the forecast period of 2020 to 2027. U.K. is growing with the highest CAGR as this is a developed country and more number of diagnostic companies is present in the country. Additionally, advancements of interventional X-ray technique and presence of leading companies in the region have also generated new prospects for iodinated contrast media in interventional X-ray.
The country section of the iodinated contrast media in interventional X-ray market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, and regulatory scenario and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Rising Prevalence of Chronic Disease and Preference for Preventive Health Check-Ups
Iodinated contrast media in interventional X-ray market also provides you with detailed market analysis for every country growth in installed base of different kind of products for iodinated contrast media in interventional X-ray market, impact of technology using life line curves and changes in automobile regulatory scenarios and their impact on the iodinated contrast media in interventional X-ray market. The data is available for historic period 2010 to 2018.
Competitive Landscape and Iodinated Contrast Media in Interventional X-Ray Market Share Analysis
Iodinated contrast media in interventional X-ray market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to iodinated contrast media in interventional X-ray market.
The major players covered in the report are Bayer AG, Iso-Tex Diagnostics, Inc., Bracco Diagnostic Inc., Novalek Pharmaceuticals Pvt. Ltd., iMAX, Taejoon Pharm, Unijules life science Ltd, General Electric, Guerbet LLC, J.B.Chemicals & Pharmaceuticals Ltd among others players domestic and global. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
- In June 2019, General Electric and Daiichi Sankyo Company did an agreement that Daiichi Sankyo to transfer authorization of marketing rights for four diagnostic imaging agents in Japan to GE Healthcare. After completing this agreement, the company expanded their diagnostic imaging agents in the Japan. This will help company to expand their business in the market.
- In July 2018, General Electric announced that they have launched ready-to-drink oral solution of iodinated contrast agent which can help physicians improving the visualization of diagnostic abdominal gastrointestinal tract. With this new formulation of contrast agent the company enhanced its choice of options for oral contrast agent which is available to radiologists and patients.
Such investment and partnership other strategies enhances the company market share with increased coverage and presence. It also provides the benefit for organisation to improve their offering for iodinated contrast media in interventional X-ray through expanded model range.